Trial Bank
Overview
378 trials match
Observational studies (…) are hidden. Tick 'Include observational studies' to show them.
A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Dru
A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS
MSMS (type not specified)Phase 1Phase 2SuspendedAssistance Publique Hopitaux De Paris · 2024 · 80 participants
Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neur
Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.
Optic neuritisNot a drug-phase studyTerminatedMedical University of Bialystok · 2020 · 7 participants
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimm
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
MSMS (type not specified)Phase 1WithdrawnBeijing Boren Hospital · 2025 · 0 participants
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants wit
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)
MSRelapsing and progressivePhase 1SuspendedCelgene Corp. · 2024 · 56 participants
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
MSMS (type not specified)Phase 4WithdrawnTulane University · 2026 · 0 participants
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relap
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
MSProgressive MSEarly phase 1WithdrawnUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · 2026 · 0 participants
A Study of LY3541860 in Adult Participants With Relapsing Multiple Scl
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
MSRelapsing and progressivePhase 2TerminatedEli Lilly and Company · 2024 · 63 participants
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Pat
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
MSMS (type not specified)Phase 1Phase 2TerminatedSwanBio Therapeutics, Inc. · 2022 · 9 participants
Brain and Behavioral Influences on Motor Skill Learning in Multiple Sc
Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis
MSRelapsing MSNot a drug-phase studyWithdrawnWayne State University · 2020 · 0 participants
Feasibility of Remote Exercise Training for Hispanics/Latinos With MS
Feasibility of Remote Exercise Training for Hispanics/Latinos With MS
MSMS (type not specified)Not a drug-phase studyTerminatedUniversity of Illinois Chicago · 2024 · 33 participants
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
MSRelapsing MSPhase 3Terminatedacetaminophen, acyclovir, alemtuzumab · Genzyme, a Sanofi Company · 2017 · 16 participants
MRI Hippocampal Microstructure and Episodic Memory in Early Multiple S
MRI Hippocampal Microstructure and Episodic Memory in Early Multiple Sclerosis
MSEarly (CIS/RIS)Not a drug-phase studyTerminatedUniversity Hospital, Bordeaux · 2019 · 84 participants
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in P
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
MSRelapsing and progressivePhase 1Phase 2WithdrawnCabaletta Bio · 2026 · 0 participants
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neuro
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
MOGADMSNMOSDPhase 1WithdrawnUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · 2025 · 0 participants
Tear Analysis in the Diagnosis of Multiple Sclerosis
Tear Analysis in the Diagnosis of Multiple Sclerosis
MSProgressive MSNot a drug-phase studyTerminatedLille Catholic University · 2011 · 80 participants
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
MSMS (type not specified)Phase 2Terminatedmethotrexate, mycophenolate mofetil, tozinameran · National Institute of Allergy and Infectious Diseases (NIAID) · 2021 · 258 participants
Tracking Peripheral Immune Cell Infiltration of the Brain in Central I
Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
MSMS (type not specified)Phase 1SuspendedUniversity of Alabama at Birmingham · 2021 · 120 participants
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
MSMS (type not specified)Phase 2Phase 3Terminatedrimabotulinumtoxinb · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC · 2021 · 32 participants
Adjunctive Gypenosides for Acute Optic Neuritis
Adjunctive Gypenosides for Acute Optic Neuritis
Optic neuritisPhase 2TerminatedFirst Affiliated Hospital of Guangxi Medical University · 2017 · 10 participants
Conventional Vestibular Training Versus Immersive Virtual Reality- Bas
Conventional Vestibular Training Versus Immersive Virtual Reality- Based Vestibular in Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyWithdrawnMaria Jesus Casuso-Holgado · 2026 · 0 participants
Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthal
Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis
MSMS (type not specified)Phase 3Terminatedclemastine, dalfampridine · Amsterdam UMC, location VUmc · 2022 · 47 participants
Masitinib in the Treatment of Patients With Primary Progressive or Non
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
MSProgressive MSPhase 3Suspendedmasitinib · AB Science · 2022 · 800 participants
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSD
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
NMOSDPhase 2Terminatedzanubrutinib · Xuanwu Hospital, Beijing · 2022 · 6 participants
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
MSProgressive MSPhase 2TerminatedMapi Pharma Ltd. · 2017 · 30 participants
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
NMOSDPhase 3TerminatedRemeGen Co., Ltd. · 2018 · 178 participants
About this data
Where the data comes from
ClinicalTrials.gov, the EU Clinical Trials Register, ISRCTN, ChEMBL and Europe PMC, combined into the MSFrontier trial bank.
How it is collected
Registry records are collected automatically, duplicate records across registries are merged, and treatments, phases and populations are tagged by software from the registry data. When an error is reported, we fix the rule so the fix applies to every trial, and log it in the Corrections log.
Last update
Trial bank updated recently. Sources and corrections